Dexamphetamine vs Vyvanse vs Ritalin: how your GP chooses

Dexamphetamine, Vyvanse (lisdexamfetamine) and Ritalin (methylphenidate) are the three stimulant medicines Australian GPs prescribe most often for ADHD. Dexamphetamine and Vyvanse are amphetamines. Ritalin is a different class, methylphenidate. Your GP weighs up how long each one lasts, what it costs on the PBS, and which class suits your side effects. The right choice is individual.

In this article

• The three medicines at a glance
• How each medication works
• Duration of action: short-acting vs long-acting
• Vyvanse vs Ritalin: what’s the difference
• PBS listing and cost in Australia
• TGA-approved indications and age ranges
• When GPs choose one over another
• Switching between stimulant medications
• Frequently asked questions

The three medicines at a glance

Figures below come from the TGA-approved product information and the PBS Schedule. Each is explained further down the page.

	Dexamphetamine	Vyvanse (lisdexamfetamine)	Methylphenidate (Ritalin, Ritalin LA, Concerta)
Active ingredient	Dexamfetamine sulfate	Lisdexamfetamine dimesylate	Methylphenidate hydrochloride
Class	Amphetamine	Amphetamine (prodrug)	Non-amphetamine stimulant
Onset	Blood levels peak about 2 hours after a dose	Gradual: converted in the bloodstream, not all at once	Concerta about 1.5 hours; not stated for the tablets or Ritalin LA
Duration	Doses 4 to 6 hours apart; one dose does not cover a full day	Effects still evident at 13 hours (children) and 14 hours (adults)	Concerta 12 hours; tablets need re-dosing through the day
Doses per day	2 to 3	1	1 (long-acting) or 2 to 3 (tablets)
PBS listing for adults	Yes, no age restriction	Yes, including a diagnosis made after 18	Ritalin LA and tablets: yes, including a diagnosis after 18. Concerta: only if diagnosed at 6 to 18
TGA-approved ages	Product information covers children; adult use is off-label but standard and PBS-subsidised	No upper age stated; not studied under 6 or over 55	From 6 years; for adults the product information specifies Ritalin LA, not the tablet
Why a GP might choose it	Cheapest on the PBS, flexible dosing, fine titration	One dose covers the day, smoother onset and offset, lower misuse potential	Different mechanism; useful with a tic history or amphetamine side effects

How each medication works

All three stimulants increase dopamine and noradrenaline in the brain, but they get there differently, and that matters clinically.

Dexamphetamine (sometimes called “dexies”, the common name for dexamphetamine tablets) is a direct-acting amphetamine. It prompts the release of dopamine and noradrenaline from nerve cells and blocks their reuptake at the same time, so both neurotransmitters build up in the synapse. Blood levels peak around 2 hours after a dose.

Lisdexamfetamine (Vyvanse) is a prodrug: the capsule itself is inactive. Red blood cells clip off an amino acid to release dexamphetamine into your bloodstream, a conversion that happens gradually rather than all at once. Patients report that protein-breakfast helps with their Vyvanse absorption.

Methylphenidate (Ritalin) works differently again. Rather than triggering release, it blocks the transporters that normally clear dopamine and noradrenaline out of the synapse. The end result, more of both chemicals available, is similar to the amphetamines, but the mechanism is distinct. That is why some people respond well to one class and not the other.

Duration of action: short-acting vs long-acting

Duration of action is one of the biggest factors in medication choice. A medicine that wears off by early afternoon makes for a different day than one that lasts into the evening.

Short-acting formulations

Dexamphetamine tablets are usually taken two to three times a day, spaced 4 to 6 hours apart, because one dose does not cover a full day on its own. This allows flexible dosing, including a smaller afternoon dose or a medication-free evening, but it does mean remembering more than one dose.

Immediate-release methylphenidate (Ritalin) works the same way: usually taken two to three times a day, so the level in your body rises and falls through the day rather than staying level.

Long-acting formulations

Lisdexamfetamine (Vyvanse) is designed for one dose in the morning. In TGA-reviewed trials, effects were still evident 13 hours after dosing in children and 14 hours in adults, so a single dose is designed to carry the whole day and into the evening for most people.

Concerta, a modified-release methylphenidate, is designed to work for 12 hours from one morning dose: the outer layer dissolves quickly, then the medicine releases gradually over the following hours. Ritalin LA, another long-acting capsule, has no duration of effect stated in its approved product information.

Vyvanse vs Ritalin: what’s the difference

Vyvanse and Ritalin are the pairing people search for most, and the pairing that confuses people most, because the names get used almost interchangeably online. They are not interchangeable.

Class is the first difference. Vyvanse is an amphetamine, a prodrug that becomes dexamphetamine in your body. Ritalin is methylphenidate, a stimulant from a different chemical family with a different mechanism. Someone who does not respond well, or has side effects, on one class often does better on the other.

Duration is the second difference. One Vyvanse dose in the morning carries the whole day, with effects still evident 13 to 14 hours later. Ritalin’s short-acting tablet needs re-dosing two or three times a day; Concerta, its long-acting form, lasts around 12 hours from a single dose.

Cost is close to a non-issue for most patients. Both are PBS-subsidised for adults (Concerta has one extra condition, covered below), so once you’re on the subsidised listing, the co-payment is the standard PBS amount either way: $25.00 general, $7.70 concession, from 1 January 2026.

Who suits which comes down to fit, not superiority. Vyvanse tends to suit people who want one dose to carry the day. Ritalin or Concerta tends to suit people who have not responded well to amphetamines, who have a history of tics, or whose GP wants to try a different mechanism because of side effects on the amphetamine class.

PBS listing and cost in Australia

Cost shapes medication choice in practice. All three stimulants are listed on the Pharmaceutical Benefits Scheme (PBS), but the listing history and out-of-pocket cost differ.

Dexamphetamine has the broadest PBS listing of the three, with no age restriction for adults, and the lowest cost per script, which is part of why it remains a common starting point.

Lisdexamfetamine (Vyvanse) was PBS-listed for children and adolescents in September 2015, and for adults, including people diagnosed after turning 18, since February 2021.

Methylphenidate (Ritalin, Ritalin LA, Concerta) is PBS-listed for ADHD, with one exception. PBS subsidy for Concerta and similar long-acting brands currently requires your ADHD diagnosis to have been made between the ages of 6 and 18. If you were diagnosed as an adult, Ritalin LA, the short-acting tablet, dexamphetamine and Vyvanse all have a PBS pathway; Concerta-style brands, at present, do not.

With PBS subsidy, the co-payment for any of these medicines is the standard PBS amount: $25.00 general and $7.70 concession, from 1 January 2026, under the National Health Amendment (Cheaper Medicines) Act 2025. If your medication is not subsidised for your situation, you will pay the full private price, and your GP will tell you before writing the script. See our guide to Medicare rebates for ADHD assessments.

TGA-approved indications and age ranges

The Therapeutic Goods Administration (TGA) approves each medicine’s product information for specific populations, and this does not always match how the medicine is actually used and subsidised in Australian general practice.

• Dexamphetamine: TGA-approved product information covers hyperkinetic behaviour disorders in children (not recommended under 3 years), with no specific adult ADHD indication. Adult use is off-label but standard practice, and is PBS-subsidised with no age restriction.
• Lisdexamfetamine (Vyvanse): TGA-approved for ADHD with no stated upper age limit, though not studied in children under 6 or adults over 55. Also TGA-approved for moderate to severe binge eating disorder in adults, managed by a psychiatrist, but not for weight loss.
• Methylphenidate: covers children from 6 years, with no stated upper limit for the short-acting tablet. For adults, product information specifies the long-acting Ritalin LA capsule rather than the short-acting tablet, though PBS-subsidised prescribing of the short-acting tablet for adults still happens in practice. Concerta has not been studied over 65.

Off-label prescribing, within a GP’s clinical judgement, is legal and common. Your GP will tell you if it applies to you.

When GPs choose one over another

There is no single best ADHD medication. Your GP weighs up several things when recommending a starting point, and adjusts from there based on how you respond.

Vyvanse is often a first choice because

• One morning dose covers a full working day. However, Dexampthetamine is often prescribed in the afternoon over time if patients report Vyvance wearing off too early.
• The prodrug mechanism gives a smoother onset and offset, which reduces the “crash” some people get with immediate-release stimulants
• It has a lower misuse potential, because the prodrug has to be converted by your body first, so crushing or injecting it does not produce a faster effect
• It is PBS-listed for adults, so the cost is subsidised

Dexamphetamine suits people who

• Need flexible dosing, including medication-free evenings
• Find long-acting formulations interfere with sleep
• Want the lowest-cost option on the PBS
• Want to titrate in small steps

Methylphenidate (Ritalin or Concerta) is often preferred when

• The amphetamine class has not worked well
• Amphetamine side effects are troublesome, such as appetite suppression, anxiety or irritability (see what to expect in the first three months on ADHD medication)
• There is a history of tics, which amphetamines are more likely to worsen
• Comorbid anxiety is present and a different mechanism is worth trying
• A shorter long-acting option than Vyvanse suits your day better

Your GP will typically start with one medication, monitor your response over several weeks, and adjust the dose from there. See our guides to adjusting your ADHD medication dose and what your GP checks during monitoring. If stimulants are not suitable at all, non-stimulant medications are an option, and our guide to getting the best results from Vyvanse covers what to expect on that medicine specifically.

Switching between stimulant medications

Switching is common and is not a sign that treatment has failed. Some adults with ADHD try more than one medication before finding the right fit.

If your GP started you on Vyvanse and the side effects are difficult, they might move you to dexamphetamine for more flexibility, or to methylphenidate if the amphetamine class is not suiting you. The reverse applies too: if methylphenidate is not controlling symptoms well enough, an amphetamine-class medicine is often the next step. Read our guide to adjusting your ADHD medication dose before assuming a full switch is needed.

Moving between dexamphetamine and Vyvanse is more straightforward than moving between drug classes, because both deliver the same active molecule. It is not a milligram-for-milligram swap, though: lisdexamfetamine is a prodrug, so the two are not interchangeable on a fixed ratio. Your GP titrates the new medicine based on how you respond, not a formula.

Who can start you on which medicine also depends on where you live. GPs can diagnose and start ADHD medication, including Vyvanse, in Queensland (any specialist GP, since 1 December 2025), South Australia (RACGP-trained GPs, since 28 February 2026), Western Australia (accredited GPs, patients 10 and over, from August 2026) and Tasmania (trained GPs, per patient). In New South Wales, Victoria, the ACT and the Northern Territory, a GP can currently only continue treatment a specialist started. See our state-by-state guide to where GPs can prescribe ADHD medication.

This page is general information about ADHD medication in Australia, not advice about your individual treatment. Do not start, stop or change a dose without talking to the clinician who prescribed it. If you experience chest pain, fainting, or thoughts of self-harm, contact your prescriber or call emergency services on 000.

Frequently asked questions

Where GPs can prescribe ADHD medication, state by state
Find a GP who assesses ADHD in your state

Sources

• TGA Product Information: Dexamfetamine (Aspen Pharmacare Australia), TGA eBS document CP-2023-PI-02524-1, revised 20 August 2025 (read 3 September 2026)
• TGA Product Information: Vyvanse, lisdexamfetamine (Takeda Pharmaceuticals Australia), TGA eBS document CP-2013-PI-02051-1, revised 1 April 2026 (read 3 September 2026)
• TGA Product Information: Ritalin and Ritalin LA, methylphenidate (Novartis Pharmaceuticals Australia), TGA eBS document CP-2010-PI-03175-3, revised 23 July 2026 (read 3 September 2026)
• TGA Product Information: Concerta, methylphenidate OROS (Janssen-Cilag), TGA eBS document CP-2009-PI-00919-3, revised 24 March 2026 (read 3 September 2026)
• PBS Schedule of Pharmaceutical Benefits, September 2026 (read 3 September 2026)
• PBS explanatory notes: patient charges, pbs.gov.au/info/healthpro/explanatory-notes/front/fee (read 3 September 2026)
• PBS Drug Utilisation Sub-Committee, Lisdexamfetamine Public Release Document, September 2023, and PBS Medicine Status Website listing history (read 3 September 2026)
• TGA Medicine Shortage Reports Database and “About the shortage of methylphenidate hydrochloride products” (read 3 September 2026)
• AADPA Australian Evidence-Based Clinical Practice Guideline for ADHD, First Edition, October 2022